Ultragenyx Pharmaceutical Inc. (RARE) stock
RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.48−0.74 (-4.30%)
Close on Nov 20, 2026Market cap $1.62BP/E –Yield –
Ultragenyx Pharmaceutical revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Ultragenyx Pharmaceutical's revenue for the twelve months ending Jun 30, 2026 was $717.21M, up 17.5% year over year. For fiscal 2025 it was $673.00M, up 20.2% from the year before. The highest annual figure on record is $673.00M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $673.00M | +20.2% |
| FY2024 | Dec 31, 2024 | $560.00M | +29.0% |
| FY2023 | Dec 31, 2023 | $434.00M | +19.5% |
| FY2022 | Dec 31, 2022 | $363.33M | +3.4% |
| FY2021 | Dec 31, 2021 | $351.41M | +29.7% |
| FY2020 | Dec 31, 2020 | $271.03M | +161.3% |
| FY2019 | Dec 31, 2019 | $103.71M | +101.4% |
| FY2018 | Dec 31, 2018 | $51.50M | +1871.5% |
| FY2017 | Dec 31, 2017 | $2.61M | +1863.9% |
| FY2016 | Dec 31, 2016 | $133.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $214.00M | +28.1% |
| Q1 FY2026 | Mar 31, 2026 | $136.00M | -2.2% |
| Q4 FY2025 | Dec 31, 2025 | $207.28M | +25.9% |
| Q3 FY2025 | Sep 30, 2025 | $159.93M | +14.7% |
| Q2 FY2025 | Jun 30, 2025 | $167.00M | +13.6% |
| Q1 FY2025 | Mar 31, 2025 | $139.00M | +27.7% |
| Q4 FY2024 | Dec 31, 2024 | $164.65M | +29.5% |
| Q3 FY2024 | Sep 30, 2024 | $139.49M | +42.3% |
| Q2 FY2024 | Jun 30, 2024 | $147.03M | +35.7% |
| Q1 FY2024 | Mar 31, 2024 | $108.83M | +8.3% |
| Q4 FY2023 | Dec 31, 2023 | $127.14M | +23.0% |
| Q3 FY2023 | Sep 30, 2023 | $98.05M | +8.1% |
| Q2 FY2023 | Jun 30, 2023 | $108.31M | +21.2% |
| Q1 FY2023 | Mar 31, 2023 | $100.50M | +25.7% |
| Q4 FY2022 | Dec 31, 2022 | $103.35M | +23.9% |
| Q3 FY2022 | Sep 30, 2022 | $90.70M | +11.1% |
| Q2 FY2022 | Jun 30, 2022 | $89.34M | +2.7% |
| Q1 FY2022 | Mar 31, 2022 | $79.94M | -19.6% |
| Q4 FY2021 | Dec 31, 2021 | $83.39M | -8.9% |
| Q3 FY2021 | Sep 30, 2021 | $81.65M | +0.2% |
| Q2 FY2021 | Jun 30, 2021 | $86.98M | +40.9% |
| Q1 FY2021 | Mar 31, 2021 | $99.40M | +173.7% |
| Q4 FY2020 | Dec 31, 2020 | $91.54M | +157.2% |
| Q3 FY2020 | Sep 30, 2020 | $81.47M | +215.8% |
| Q2 FY2020 | Jun 30, 2020 | $61.71M | +155.5% |
| Q1 FY2020 | Mar 31, 2020 | $36.31M | +99.8% |
| Q4 FY2019 | Dec 31, 2019 | $35.59M | +118.9% |
| Q3 FY2019 | Sep 30, 2019 | $25.80M | +119.3% |
| Q2 FY2019 | Jun 30, 2019 | $24.15M | +88.8% |
| Q1 FY2019 | Mar 31, 2019 | $18.17M | +70.2% |
| Q4 FY2018 | Dec 31, 2018 | $16.26M | +573.6% |
| Q3 FY2018 | Sep 30, 2018 | $11.76M | +5840.9% |
| Q2 FY2018 | Jun 30, 2018 | $12.79M | +255780.0% |
| Q1 FY2018 | Mar 31, 2018 | $10.68M | +9518.9% |
| Q4 FY2017 | Dec 31, 2017 | $2.41M | – |
| Q3 FY2017 | Sep 30, 2017 | $198.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $5.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $111.00K | – |
See a number that looks wrong?